Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

Key Insights Silence Therapeutics' significant insider ownership suggests inherent interests in company's expansion ...

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice ...

Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.

Silence Therapeutics plc's Zerlasiran showed significant Lp(a) reduction but was overshadowed by Eli Lilly's oral Muvalaplin, which offers similar efficacy with easier administration and potentially ...

Silence Therapeutics plc (SLN) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Detailed price information for Silence Therapeutics Plc ADR (SLN-Q) from The Globe and Mail including charting and trades.

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...

SLN is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of SLN shares has increased $0.08 since the market last closed. This is a 1.18% ...